Skip to main content
. Author manuscript; available in PMC: 2014 Jun 10.
Published in final edited form as: Expert Opin Ther Targets. 2012 Feb 17;16(3):313–324. doi: 10.1517/14728222.2012.662956

Figure 3. Schematic diagram of strategies targeting the JAK2 pathway in MPNs.

Figure 3

Functional expression of JAK2 can be blocked at several levels. Deacetylase inhibitors (DACi) increase the acetylation and thus inhibit the chaperone function of HSP90 (heat shock protein 90). Inhibition of HSP90 leads to a reduction in levels of matured JAK2. Specific tyrosine kinase inhibitors prevent activation of downstream signaling cascades. Indicated are drugs that are currently in clinical trials for the treatment of MPNs. (see also http://cliniclatrials.gov)